U.S. May Launch Section 301 Investigation Into Swiss Pharmaceutical Industry, Roche and Novartis Face Tariff Risks
Alina Collins
Switzerland's pharma lobby warned that the U.S. may open a Section 301 investigation over planned drug-price cuts, putting Roche and Novartis's U.S. export chains under direct pressure as pharma tariff risk spreads from Germany to Switzerland.
What is a Section 301 probe, and why is Switzerland a target?
Section 301 — a U.S. Trade Act tool that lets Washington investigate "unfair trade practices" and impose tariffs — was formally launched against Germany last week after Berlin moved to cut drug spending.
Switzerland is now revising its health-insurance laws to lower mandatory drug prices. This means → Washington sees Switzerland doing the same thing: shifting innovation costs onto American consumers.
Interpharma CEO René Buholzer said publicly: "Switzerland is clearly a potential target too." In plain terms = when the industry itself flags the risk first, insiders judge the probability as meaningful.
What are U.S. lawmakers pushing for?
Republican members of Congress this month wrote to the U.S. Trade Representative and Commerce Secretary, demanding Section 301 probes into unfair foreign drug pricing.
The letter named Germany and Switzerland specifically, accusing both of "doubling down on relying on the U.S. to bear innovation costs."
This means → the pressure is not just from the White House. Congress is driving it too, and the political momentum for a probe has already formed.
Why are Roche and Novartis most exposed?
Switzerland is home to Roche and Novartis. Pharma and chemical products accounted for over half of Swiss exports last year.
If a probe leads to tariffs, both companies' U.S. export chains face direct impact — the U.S. is the world's largest drug market, and that revenue line is not replaceable.
This reflects a bigger pattern: Washington is turning "drug-price fairness" into a trade weapon, expanding its crosshairs from Germany to Switzerland. Who comes next is an open question.
What does Germany's experience tell us?
Germany announced statutory health-system reforms and drug-spending cuts in April. The U.S. formally launched a 301 probe last week in response.
But Reuters reports that Berlin, facing pushback from pharma companies, is already looking to scale back the plan.
In plain terms = Germany's lesson is clear: the U.S. probe threat works — the government backed down under pressure. Whether Switzerland follows the same path is the variable markets need to watch.
Content is for reference only, not financial advice.